The efficacy of aspirin for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) has been well established in both men and women1; however, evidence on aspirin use for primary prevention has been controversial. In 2022, the US Preventive Services Task Force (USPSTF) released new recommendations that advise against the use of aspirin for primary prevention of ASCVD in adults 60 years or older (grade D; recommend against initiating),2 with no differences in treatment effect or guidance by sex. For primary prevention in individuals aged 40 to 59 years who have an estimated 10-year ASCVD risk of at least 10% per the American College of Cardiology/American Heart Association pooled cohort equations, a grade C recommendation was given, indicating that there is at least moderate certainty that the net benefit in this group is small and shared decision-making should be considered on a case-by-case basis.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Chrisandra L. Shufelt, MD, MS, Mayo Clinic Women's Health and Division of General Internal Medicine, Jacksonville, FL, 4500 San Pablo Road, Jacksonville, Florida 32224 (email@example.com).
Published Online: July 25, 2022. doi:10.1001/jama.2022.11951
Conflict of Interest Disclosures: Dr Mora and Dr Manson are co-developers of the Aspirin-Guide mobile application. Dr Mora reported receiving personal fees from Pfizer and Quest Diagnostics outside the submitted work. No other disclosures were reported.
You currently have no searches saved.
You currently have no courses saved.